TYK Medicines, Inc (HKG:2410)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
27.50
+0.05 (0.18%)
Apr 24, 2025, 4:08 PM HKT
89.92%
Market Cap 10.18B
Revenue (ttm) 113.87K
Net Income (ttm) -411.79M
Shares Out 370.84M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,692,500
Average Volume 2,625,475
Open 27.30
Previous Close 27.45
Day's Range 26.45 - 27.50
52-Week Range 12.86 - 56.55
Beta n/a
RSI 45.68
Earnings Date Mar 27, 2025

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-depe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 153
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2410
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.